| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
125.61(B) |
| Last
Volume: |
944,433 |
Avg
Vol: |
1,608,675 |
| 52
Week Range: |
$332.58 - $485.53 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
40,257 |
161,595 |
276,622 |
637,091 |
| Total Sell Value |
$18,057,339 |
$68,277,055 |
$109,821,201 |
$217,614,554 |
| Total People Sold |
10 |
13 |
14 |
18 |
| Total Sell Transactions |
14 |
47 |
70 |
137 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kewalramani Reshma |
EVP and CMO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
22,187 |
35,285 |
|
- |
|
| Wagner Charles F Jr |
EVP and CFO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
14,021 |
17,816 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
35,293 |
71,483 |
|
- |
|
| Bozic Carmen |
EVP, GMDA |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
12,421 |
14,518 |
|
- |
|
| Tatsis Ourania |
SVP, CRO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
9,694 |
16,946 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
38,757 |
70,310 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
34,323 |
67,563 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
36,693 |
68,246 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
12,464 |
30,223 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-02-05 |
4 |
AS |
$240.59 |
$484,763 |
D/D |
(2,000) |
1,875 |
|
14% |
|
| Lee Yuchun |
Director |
– • – |
2020-02-05 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-02-04 |
4 |
AS |
$235.15 |
$477,672 |
D/D |
(2,000) |
1,875 |
|
12% |
|
| Lee Yuchun |
Director |
– • – |
2020-02-04 |
4 |
OE |
$57.27 |
$173,414 |
D/D |
3,028 |
3,875 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-03 |
4 |
AS |
$228.91 |
$484,939 |
D/D |
(2,099) |
17,759 |
|
18% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$187,449 |
D/D |
2,099 |
19,858 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-03 |
4 |
AS |
$228.89 |
$946,845 |
D/D |
(4,097) |
36,190 |
|
18% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$364,239 |
D/D |
4,097 |
40,287 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-03 |
4 |
AS |
$229.35 |
$953,861 |
D/D |
(4,126) |
31,553 |
|
18% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
35,679 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-03 |
4 |
AS |
$228.90 |
$857,465 |
D/D |
(3,710) |
33,240 |
|
18% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$330,756 |
D/D |
3,710 |
36,950 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-02-03 |
4 |
AS |
$229.39 |
$462,196 |
D/D |
(2,000) |
847 |
|
18% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-03 |
4 |
AS |
$229.07 |
$1,025,350 |
D/D |
(4,436) |
31,553 |
|
18% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
35,989 |
|
- |
|
| Sachs Bruce I |
Director |
– • – |
2020-01-31 |
4 |
AS |
$224.02 |
$4,559,830 |
D/D |
(20,000) |
11,210 |
|
16% |
|
1777 Records found
|
|
Page 27 of 72 |
|
|
2.49 (0.51%) 
